High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients

Cancer Investigation

Volumn 28, Issue 10, 2010, Pages 1078-1083

  Ren, Shengxiang ^a   Zhou, Songwen ^a   Zhang, Ling ^a   Xu, Jianfang ^a   Lv, Meijun ^a   Zhou, Caicun ^a   Zhang, Jie ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Cancer biomarkers; Chemotherapy; Lung cancer; Prognosis and response predictions

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; NAVELBINE; PACLITAXEL; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; DISEASE FREE SURVIVAL; EXCISION REPAIR; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PLEURA EFFUSION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA PURIFICATION; TREATMENT OUTCOME; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 78649302696     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357901003735659     Document Type: Article

References (25)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57, 43-66.
2. Weir, H. K.; Thun, M. J.; Hankey, B. F.; Ries, L. A.; Howe, H. L.; Wingo, P. A.; Jemal, A.; Ward, E.; Anderson, R. N.; Edwards, B. K. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003, 95, 1276-1299.
3. Ohe, Y.; Ohashi, Y.; Kubota, K.; Tamura, T.; Nakagawa, K.; Negoro, S.; Nishiwaki, Y.; Saijo, N.; Ariyoshi, Y.; Fukuoka, M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18, 317-323.
4. Pfister, D. G.; Johnson, D. H.; Azzoli, C. G.; Sause, W.; Smith, T. J.; Baker, S., Jr.; Olak, J.; Stover, D.; Strawn, J. R.; Turrisi, A. T.; Somerfield, M. R.; American Society of Clinical Oncology. J Clin Oncol 2004, 22, 330-353.
5. Schiller, J. H.; Harrington, D.; Belani, C. P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D. H.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346, 92-98.
6. Solomon, B.; Bunn, P. A., Jr. Adjuvant chemotherapy for non-small cell lung cancer. Cancer Invest 2007, 25 (4), 217-225.
7. Boldrini, L.; Gisfredi, S.; Ursino, S.; Lucchi, M.; Greco, G.; Fontanini, G. Effect of the p53 codon 72 and intron 3 polymorphisms on nonsmall cell lung cancer (NSCLC) prognosis. Cancer Invest 2008, 26 (2), 168-172.
8. Reardon, J. T.; Vaisman, A.; Chaney, S. G.; Sancar, A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bisaceto-ammine- dichloro-cyclohexylamineplatinum (IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999, 59, 3968-3971.
9. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22, 7265-7279.
10. Reed, E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005, 11, 6100-6102.
11. Niedernhofer, L. J.; Odijk, H.; Budzowska, M.; van Drunen, E.; Maas, A.; Theil, A. F.; de Wit, J.; Jaspers, N. G.; Beverloo, H. B.; Hoeijmakers, J. H.; Kanaar, R. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-linkinduced double-strand breaks. Mol Cell Biol 2004, 24, 5776-5787.
12. Rosell, R.; Taron, M.; Ariza, A.; Barnadas, A.; Mate, J. L.; Reguart, N.; Margel, M.; Felip, E.; Méndez, P.; García-Campelo, R. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004, 31, 20-27.
13. Olaussen, K. A.; Dunant, A.; Fouret, P. DNA repair by ERCC1 in nonsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355 (10), 983-991.
14. Smith, S.; Su, D.; Rigault de la Longrais, I.; Schwartz, P.; Puopolo, M.; Rutherford, T. J.; Mor, G.; Yu, H.; Katsaros, D. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007, 25, 5172-5179.
15. Ceppi, P.; Volante, M.; Novello, S.; Rapa, I.; Danenberg, K. D.; Danenberg, P. V.; Cambieri, A.; Selvaggi, G.; Saviozzi, S.; Calogero, R.; Papotti, M.; Scagliotti, G. V. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17, 1818-1825.
16. Lord, R.; Brabender, J.; Gandara, D.; Alberola, V.; Camps, C.; Domine, M.; Cardenal, F.; Sánchez, J. M.; Gumerlock, P. H.; Tarón, M.; Sánchez, J. J.; Danenberg, K. D.; Danenberg, P. V.; Rosell, R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8, 2286-2291.
17. Therasse, P.; Arbuck, S. G.; Eisenhauer, E. A.; Wanders, J.; Kaplan, R. S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A. T.; Christian, M. C.; Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92, 205-216. (Pubitemid 30099779)
18. Li, Q.; Yu, J. J.; Mu, C.; Yunmbam, M. K.; Slavsky, D.; Cross, C. L.; Bostick-Bruton, F.; Reed, E. Association between the level of damage in human ovarian cancer cells. Anticancer Res 2000, 20, 645-652.
19. Lee, K. H.; Min, H. S.; Han, S. W.; Oh, D. Y.; Lee, S. H.; Kim, D. W.; Kim, D. W.; Im, S. A.; Chung, D. H.; Kim, Y. T.; Kim, T. Y.; Heo, D. S.; Bang, Y. J.; Sung, S. W.; Kim, J. H. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008, 60, 401-407.
20. Fujii, T.; Toyooka, S.; Ichimura, K.; Fujiwara, Y.; Hotta, K.; Soh, J.; Soh, J.; Suehisa, H.; Kobayashi, N.; Aoe, M.; Yoshino, T.; Kiura, K.; Date, H. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 2008, 59, 377-384.
21. Azuma, K.; Sasada, T.; Kawahara, A.; Takamori, S.; Hattori, S.; Ikeda, J.; Itoh, K.; Yamada, A.; Kage, M.; Kuwano, M.; Aizawa, H. Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009, 64 (3), 326-333.
22. Lee, H. W.; Choi, Y. W.; Han, J. H.; Kim, J. H.; Jung, J. H.; Jeong, S. H.; Kang, S. Y.; Choi, J. H.; Oh, Y. T.; Park, K. J.; Hwang, S. C.; Sheen, S. S. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 2009, 65, 377-382.
23. Ota, S.; Ishii, G.; Goto, K.; Kubota, K.; Kim, Y. H.; Kim, Y. H.; Kojika, M.; Murata, Y.; Yamazaki, M.; Nishiwaki, Y.; Eguchi, K.; Ochiai, A. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009, 64, 98-104.
24. Cobo, M.; Isla, D.; Massuti, B.; Montes, A.; Sanchez, J. M.; Provencio, M.; Viñolas, N.; Paz-Ares, L.; Lopez-Vivanco, G.; Muñoz, M. A.; Felip, E.; Alberola, V.; Camps, C.; Domine, M.; Sanchez, J. J.; Sanchez-Ronco, M.; Danenberg, K.; Taron, M.; Gandara, D.; Rosell, R. Customizing cisplatin based on quantitative excision repair crosscomplementing 1 mRNA expression: a phase III trial in non-smallcell lung cancer. J Clin Oncol 2007, 25 (19), 2747-2754.
25. Simon, G.; Sharma, A.; Li, X.; Hazelton, T.; Walsh, F.; Williams, C.; Chiappori, A.; Haura, E.; Tanvetyanon, T.; Antonia, S.; Cantor, A.; Bepler, G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced nonsmall-cell lung cancer. J Clin Oncol 2007, 25, 2741-2746.